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ABSTRACT 
Introduction: This evaluation determines whether published studies to date meet the key 
characteristics identified for budget impact analyses (BIA) for medicines, accomplished 
through a systematic review and assessment against identified key characteristics. Methods: 
Studies from 2001 to 2015 on "budget impact analysis" with "drug" interventions were 
assessed, selected based on their titles/abstracts and full texts, with their characteristics 
checked according to key criteria. Results: Out of 1984 studies, 92 were identified. Of these, 
95% were published in Europe and the USA. 2012 saw the largest number of publications 
(16%) with a decline thereafter. 48% met up to 6 or 7 out of the 9 key characteristics. Only 22% 
stated no conflict of interest. Conclusion: The results indicate low adherence to the key 
characteristics that should be considered for BIAs and strong conflict of interest. This is an 
issue since BIAs can be of fundamental importance in managing the entry of new medicines 
including reimbursement decisions. 
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 INTRODUCTION 
Budget Impact Analysis (BIA) is a last step in Health Technology Assessment (HTA), which 
allows health authorities to  know whether a particular new technology is safe, effective, and 
efficient as well as affordable to the health care system.   
Increasingly, BIAs are seen as an important tool in decision-making in the face of the increasing 
pressure on resources through ageing populations and the continual launch of new premium 
priced technologies [1,2]. These pressures have increased the requirement among health care 
professionals and systems to consider all aspects of new medicines as part of their decision-
making, including their potential budget impact. This reflects the growing use of horizon 
scanning and forecasting activities among health authorities, especially for new medicines [1-
3]. Consequently in recent years, health authorities and the main HTA institutions have 
expanded their guidelines to encompass BIAs [4-8]. However, BIA is not a technique that is 
currently well established in the literature. Few publications appear to meet the established 
definitions and to date published studies, including reviews, show that a number of published 
BIAs do not reach the desired quality level, and there are concerns with their findings [4,5,8].  
The current study aims to determine whether the publications not carried out by Health 
Technology Agencies meet the key characteristic for undertaking BIAs for medicines. 
Subsequently, provide guidance to all key stakeholders based on the findings from the health 
authority and/or budget holder perspective. This will be achieved through a systematic review 
of BIA studies, a verification of the characteristics adopted in each study and an analysis of the 
results according to identified key characteristics. It is not aim of this study to analyze the 
quality of published BIA studies.  
METHODS 
This systematic review of studies was carried out in accordance with the Cochrane 
Collaboration Handbook [9] guidelines and has been reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [10]. We did not 
include BIAs from HTA Agencies as our aim was not to assess the quality of BIAs but whether published 
BIAs met identified key characteristics given current concerns.  
Eligibility criteria 
Only primary studies with "budget impact analysis" design and a "drug" as a means of 
intervention were included in this review. Analyses of new medicines were accepted, as well as 
comparisons of alternative and well-establish therapeutic perspectives. Date and language of 
the publication were not exclusion criteria.  
Study search 
A systematic bibliographic search of electronic research databases and grey literature was 
performed in November 2015. This included a search of PubMed, Central (Cochrane), Centre 
for Reviews and Dissemination (University of York) and Lilacs regional databases using the 
parameters described in the eligibility criteria. The searches were conducted using strategies 
developed specifically for each database and the respective MeSH descriptors. An illustration 
of the search strategy for PubMed, Central (Cochrane) and Lilacs are included in the Appendix 
(Appendix 1A, 1B, 1C). The years ranged from 2001 until November 2015. 
  
 Study selection 
Following the search strategies, publications were organized into a program, which excluded 
duplicates, with each study randomly assigned to at least two independent blind reviewers 
among the co-authors. The reviewers selected the studies in two reading phases: titles and 
abstracts (Phase 01) and full text (Phase 02). A third reviewer helped resolve any 
disagreements. Theoretical studies, analyses performed by Health Technology Evaluation 
Agencies, dosage comparison studies and comparison of drugs with procedures or devices 
were excluded. 
Data collection and analysis 
We used a dedicated electronic form to collect the main characteristics of the publications 
included in the study. The data were collected in duplicate with each study randomly assigned 
to at least two independent blind reviewers among the co-authors.  
Selection of parameters 
According to leading publications, the main characteristics to be considered in any BIA are the 
adopted perspective, technology comparison scenarios, product and service costs, time 
horizons, populations of interest, the method of calculation, the evaluation of uncertainties 
(sensitivity analysis) and model validation. Additionally, the data must be from reliable 
sources, reflect reality, be reproducible and easy to interpret by health care managers [4-8,11]. 
In order to evaluate the selected studies, this study considered the following characteristics 
identified from the literature that BIA studies should meet and contain: features of the health 
care system in question; the perspective; the population; a scenario analysis; direct costs, time 
horizons; framework; an uncertainty evaluation, and validation. Two independent blind 
reviewers used the dedicated electronic form to collect the key characteristics in each of the 
92 selected studies. 
RESULTS 
Out of a total of 1984 publications, 92 were finally included in this systematic review. The 
breakdown of papers is described in Figure 1.  
  
 Figure 1: Breakdown of the sourced papers in the systematic review 
 
The publications retrieved were between 2001 and 2015, with more than 70% published in 
2010 or later (Figure 2).  
Figure 2 - Evolution of the quantity of BIA studies per year (n=92) 
 
The origin of the studies by continent and country where consolidated by total (2001 to 
November 2015) as well as two time periods; i.e. from 2001 to 2009 and from 2010 to 
November 2015 (Table 1), with most studies published from 2010 onwards.  
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 Table 1 - Origin of the studies by Continent and Country per periods (n=92) 
 * Until November 2015 
The greatest number of BIA studies (four) were performed for infliximab, followed by 
rosuvastatin, trastuzumab and natalizumab, with three studies each. The main disease area 
focus of the sourced studies for the systematic review was: (a) antineoplasic and 
immunomodulator agents - 34%; (b) nervous system diseases - 18%; (c) systemic anti-infection 
medicines - 16% and (d) cardiovascular system - 9%. Medicines for orphan diseases and 
diseases of the alimentary tract and metabolism, blood and hematopoietic organs, the 
respiratory system, perception organs, diseases that require systemic hormonal drugs 
excluding sexual hormones and insulins, and musculoskeletal system/alimentary tract and 
metabolic diseases accounted for the remaining studies (23%). 
Characteristics of the published studies according to the main characteristic for the 
formulation of BIAs  
Features of the health care system: 22 studies (24%) 
[12,13,15,16,18,19,26,33,35,48,51,54,77,81,83,84,86,88,92,93,100,102] described some type of 
feature of the health care system in which the analysis was performed. The most reported 
characteristics were universal health coverage (59%). 
Perspective: 82 studies (89%) [12-17,19-24,26-68,70-72,77,78,80-85,87-93,95-103] that performed 
BIA were focused on the budget holder. In all, the perspective of the 92 studies was broken 
down as follows: the public health system (59%), health insurance companies (24%), paying 
parties (10%), hospitals (5%), and society (2%). 
Population: All the studies reported the evaluated population, which was equally divided 
between the total and the sample population. Estimates of the population size of interest were 
taken from epidemiological studies (73%) and others (27%). 
Scenario analysis: At least one type of scenario comparison was reported by 83 of the studies 
(90%) [12-17,19-63,65-71,73,75-85,89-98,100,102,103]. Bearing in mind that the same study may 
have made more than one assessment: comparisons involved costs comprised 33%, 
epidemiologic data 17%, the use of different medicines 16%,  and market share 15%. These 
analyses accounted for 81% of all comparisons. The others included comparisons of standards 
of the use of technologies (12%) and comparisons of treatments (7%). 
Continent  Country (n) 
All years* 
 
2001 to 2009 
 
2010 to 2015* 
єŶ % 
 
єŶ % 
 
єŶ % 
Europe 
Spain (13) United Kingdom (11) Italy 
(8) Belgium (4) Greece (4) France (3) 
Netherlands (3) Denmark (2) Finland 
(2) Hungary (2) Germany (1) Ireland 
(1) Norway (1) Switzerland (1) 
56 60,9 
 
12 50,0 
 
44 64,7 
Americas 
USA (22) Brazil (4) Canada (3) Chile (1) 
Colombia (1) 
31 33,7 
 
12 50,0 
 
19 27,9 
Asia Thailand (2) Iran (1) 3 3,3 
 
- - 
 
3 4,4 
Africa South Africa (1) 1 1,1 
 
- - 
 
1 1,5 
Oceania Australia (1) 1 1,1 
 
- - 
 
1 1,5 
Total 92 100,0 
 
24 100,0 
 
68 100,0 
 Direct costs: 62 studies (67%) [12-20,22,24,25,29-31,35,36,38,39,41-45,47,48,50,52-61,64-67,69, 
71,72,75,76,79,81-84,89,91-93,95-97,99,100,102,103] reported the analysis of at least one of the 
costs related to the therapeutic area (i.e. cost of any diagnostics, current interventions, 
treatment of any adverse events, hospitalization, devices, supplies used, etc.) in addition to 
the costs of the medicines. The remainder considered only the medicine costs as a direct cost. 
Time horizon: 67 studies (73%) [12-14,18-20,22-24,26,27,29,30,33,35-50,52-55,57-59,61,63,64,66-
72,74-77,80-83,85,89-91,93-96,99,100,102,103] reported a time horizon from 1 to 5 years. 21 
studies (23%) reported a time horizon of 3 years. The time horizon cycle used most often in the 
calculations was one year (68%). 
Method of calculation (framework): 22 studies (24%) [12,14-16,24,26,27,29,30,33,38-
40,42,46,48,50,53,54,88,91,102] reported using some form of good practice guideline with 77% 
reported using ISPOR guidelines. Calculation methods based on a spreadsheet and a simple 
decision-making tree (static) were used in 59% of the studies. Simple calculation methods such 
as future expenditure projection without the use of a transition state model that took disease 
gravity into account were found in 28% of the studies. More complex calculation methods with 
the use of a spreadsheet and the Markov-like decision-making tree (dynamic) were employed 
in 13% of the studies. The BIA calculation method was included in 50% of the studies. 
Uncertainty evaluation: At least one type of sensitivity analysis was used to evaluate 
uncertainty in 67 studies (73%) [12-20,24,26-31,33-50,52-57,59,62,63,68,71,73,74,77-
83,85,86,89,91-97,100,102, 103]. The type of analysis most used was univariate (one way) 
analysis, employed in 76 of the studies, followed by probabilistic analysis (Monte Carlo) in 9% 
of the studies and multivariate (Multiway) analysis in 6% of the studies. Considering that the 
same study may have performed sensitivity analysis for more than one dimension, 34% of the 
analyses included costs, 22% included epidemiologic data, 15% included market share, 14% 
included clinic procedures and 8% included the recipient population. 
Validation: 5 studies (5%) [37,39,40,56,92] reported some type of BIA validation. Face validity, 
the extent to which the model corresponded to the reality as evaluated by a professional with 
experience in the problem, was adopted in four studies. Verification of mathematical 
calculations was reported in one study. 
In order to better understand the profile and course of the studies between 2001 and 2015, 
the number of key characteristics for the production of BIAs was recorded for each study. This 
was then recorded against the sum of published BIA studies for that year (Figure 3). 
  
 Figure 3 - The number of studies and the quantity of key characteristics annually (2001 to 
November 2015) (n=92) 
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Subsequently, a trend analysis was conducted regarding the key characteristics for producing 
BAIs. The average for each year was calculated by taking the sum of the number of the key 
characteristics for producing BIAs by all studies published in a given year divided by the sum of 
the studies published in that  year (Figure 4). 
  
 Figure 4 - The trend of studies according to the key characteristics for the production of BIAs 
(2001 to November 2015) (n=92) 
  
Two other characteristics were checked: 55% of the analyses reported conflict of interests, 
74% reported pharmaceutical company funding and 5% contained no details of conflicts of 
interest or funding sources. Table 2 contains details of the key characteristics of the studies 
with and without pharmaceutical company funding. 
Table 2 - Quantity of key characteristics meeting in studies with and without pharmaceutical 
company funding and conflict of interest (n=51 and 15) 
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2 
 
2 3,9 
  
- 
3 
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2 16,7 
4 
 
12 23,5 
 
3 25,0 
5 
 
7 13,7 
 
1 8,3 
6 
 
13 25,5 
 
2 16,7 
7 
 
10 19,6 
 
4 33,3 
8 
 
3 5,9 
  
- 
Total 
 
51  100,0  
 
12  100,0  
 
DISCUSSION 
The current study sought to better understand the key characteristics of the 92 identified BIAs 
studies to provide future guidance. 2010 saw the number of studies (12 in all) double in 
relation to the previous year (Figure 2). The number of published studies remained at 
approximately this level in the following 5 years. The evolution of number of studies meeting 
the 9 identified key characteristics showed that 69% met at least 5 of the key characteristics 
and 53% met 6. In 2010, 6 studies met 7 of the key characteristic. In 2012, the greatest number 
of analyzed studies (16%), 3 met 8 of the key characteristic, the best result in the study period. 
In 2014 and 2015, only 1 study per year met 8 of the key characteristic (Figure 3). There was an 
ascending line in the number of published studies meeting the key characteristics (y = 0,1142x 
+ 4.3333) (Figure 4), suggesting that the number of BIAs meeting the key characteristics should 
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 increase in the future. However, the analysis performed from 2010 presented a downward line 
(y = -0,083x + 5.8197). This is a concern. 
Other identified concerns included the fact that BIAs are typically targeted at health authority 
decision makers; however, only 24% of the studies reported anything about the health systems 
in question. In addition, only 24% of the analyzed studies reported following a good practice 
guideline or principle. One third of the sourced studies used only drug costs to make up direct 
medical costs and only 5% of the studies recorded eight of the nine characteristic for the 
production of BIAs, and none of the sourced studies recorded all nine. Overall, the lack of 
sensitivity analysis and validation were some of the main reasons for non-compliance with the 
main characteristic for BIAs. This low presence of the key characteristic for BIAs has been seen 
in previous analyses.  
Previous systematic reviews of BIAs have made important contributions to the development of 
BIAs including highlighting concerns. Mauskopf et al [4] (2005) analyzed 10 multi-country 
studies of disease records, the comparison parameters used, outcomes, study designs and the 
results obtained. Orlewska et al [5] (2009) analyzed the records of the methods used in 34 
multi-country studies and, more recently, Van de Vooren et al [8] (2014) analyzed 17 European 
BIAs studies concerning the occurrence of other economic evaluations associated with these 
analyses. Additionally, Garattini et al [6] (2011) analyzed and recorded the characteristic of BIA 
in 5 multi-country studies in an attempt to clarify the role of this type of evaluation in relation 
to other modalities of health economic evaluation. 
In 2005, Mauskopf et al [4] reported no clear methodological guidelines and that few studies 
met the BIA definition. However, the belief in the evolution of the theme was clear. In 2009, 
Orlewska and colleagues [5] confirmed that BIAs studies typically lacked the desired quality. 
However, positive changes were expected following the establishment of the investigation 
principles and good practice guidelines as a tool to codify and establish relevant questions as 
well as enhance the standardization and transparency of future BIAs studies. Frustrating the 
expectations, a recent review by Van de Vooren and colleagues [8] of European studies 
published in 2014 stated that BIA was still not a well-established technique and that many 
studies did not reach an acceptable quality. According to these authors, many of the published 
studies lack reliable data sources, i.e. estimates from other countries, assumptions from expert 
panels as well as reliable epidemiological and local cost data, and very often the results were 
given as costs per patient. These characteristics made it difficult to provide results that are 
acceptable for the local situation and key decision makers. In this way, what might be 
considered a differential in relation to other types of economic evaluation ends up being a 
weakness of many current BIAs studies.  These issues can be directly linked to the funding of 
studies and conflict of interest. Indeed, the funding of BIAs studies by pharmaceutical 
companies is a recurrent theme. This occurred in 58% of the studies analyzed by Orlewska and 
colleagues [5] (2009) and 88% of those by van de Vooren and colleagues [8] (2014). In the 
current study, only 21% of the studies reported not being supported by pharmaceutical 
companies. A similar low percentage reported a lack of conflict of interest. Of the 92 studies, 
51 (55.4%) reported pharmaceutical company funding and conflict of interest with only 12 
studies (13.0%) reporting no pharmaceutical company funding or conflict of interest (Table 2). 
33.3% of the studies without pharmaceutical company funding or conflict of interest met 7-8 
key characteristics for BIA against only 25.5% studies with funding from pharmaceutical 
companies and conflict of interest. 
 
 Studies that do not show acceptable quality, which are funded by companies and present a 
conflict of interest, may result in an appreciable credibility issue among health authority 
decision makers. Considering that most BIAs studies have focused on chronic diseases that 
require high-aggregated value treatments, with appreciable budget investment, this lack of 
credibility is a significant concern from the health system managers' viewpoint. This would 
suggest resources currently being spent by companies on the production of BIAs to support 
reimbursement, funding and utilization decisions for their new technology including new 
medicines are being wasted. In view of this, we believe that key stakeholders involved in the 
development of BIAs do not yet fully realize the power of their BIAs for health system 
management. This includes the use of BIAs to help determine the feasibility of the adoption of 
a new technology by a health system including preparing potential budgets [104,105,106]. BIA 
results enable decision-makers to know whether technologies are affordable to the users of a 
health care system and whether technologies should be adopted or not in all or specified sub-
populations in question. Moreover, BIAs may help determine the way health authorities and 
other key stakeholder groups agree how new medicines or other new technologies should be 
introduced into health care systems [2,3]. Even in the face of budgetary restraints, healthcare 
managers have the power to establish strategies that enable the adoption of new health care 
technologies, either through resource reallocation or disinvestment or even specific strategies 
such as the gradual establishment of graded clinical protocols geared at different degrees of 
patients' needs [2,3,107,108]. However for this, health care managers must have guaranteed 
high quality and a low risk of bias of BIAs. This means encouraging greater independence and 
quality in their production. We look forward to these developments to enhance the future 
utility of this important decision making tool. 
CONCLUSION 
Budget Impact Analysis is an important decision-making tool. It enables accurate (re)allocation 
of financial resources in a given health system, either through the evaluation of new 
technologies or the re-evaluation of existing technologies. Greater adherence to the key 
characteristic of good practices for BAIs has been seen in the recent years. However, most BIAs 
studies currently conducted are still far from an agreed standard of excellence. The results 
indicate low adherence to the key characteristics for the production of BIAS. Additionally, 
many studies report conflict of interest and funding from the companies. BIAs have often 
become part of company marketing strategies and away from the intended goal of providing 
short and medium term economic consequences of new technologies from a health system 
perspective. This is a concern as BIAs are of fundamental importance in budget allocation as 
well as in decisions regarding pricing and utilization of new technologies. Future studies must 
be strongly committed to high methodological quality and low bias to enhance their use 
among health authority decision makers.  
KEY  POINTS 
What is already known about the topic? 
x Budget Impact Analyses (BIA) are increasingly seen by health authority personnel as an 
important decision-making tool enabling improved accuracy in the (re)allocation of 
financial resources. However, there are concerns with the quality of current BIAs. 
What does the paper add to existing knowledge? 
x A systematic review of all studies up to November 2015 was undertaken to assess whether 
the publications meet the key characteristics for the production of BIAs for medicines. This 
 resulted in 92 identified publications meeting the strict criteria for inclusion, the majority 
(95%) of which were published in Europe or the USA;  
x Improvement in adherence to the identified key characteristics for BIA studies has been 
seen in the recent years. However,  adherence to the key characteristic of good practices 
still remains low. Furthermore, many studies report conflict of interest and industry 
funding. . 
What insights does the paper provide for informing health care-related decision-making? 
x This is a concern and suggests BIAs have increasingly become part of marketing strategies 
and away from their intended goal of providing, short and medium term economic 
consequences of technologies to health authority decision makers to help with future 
budget allocation/ investment decisions 
x Future researchers as well as commercial organisations must be committed to high 
methodological quality and low bias levels when conducting future BIAs to enhance their 
use among health authority decision makers, which should be an intended goal. 
 
Expert Commentary 
BIAs are increasingly required by health authorities across countries to help with the planning 
of budgets for new valued premium priced medicines. However, this systematic review 
demonstrated that there are still concerns with the quality of studies. This was despite 
publications suggesting that key items and features should be addressed including the health 
care system in question, the perspective, the anticipated population, direct costs, the time 
horizons and uncertainty evaluation. This has implications for their usefulness among health 
authority personnel. The most effective and promising strategies for BIAs in the future is the 
production of studies strongly committed to a high methodological quality and a low bias to 
enhance their use among health authority decision makers.  
 
Five-year Review 
It is envisaged that the quality of BIA studies will increase with increasing  consciousness 
among those that produce them, including pharmaceutical companies, that BIAs are of 
fundamental importance in budget allocation as well as in decisions regarding the pricing and 
utilization of new technologies including new premium priced medicines.  This will be possible 
over the next few years with agreement and consolidation of BIA methodologies. 
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KZ “ƵĚŐĞƚŝŵƉĂĐƚŵŽĚĞůƐ ?KZ “ƵĚŐĞƚĂƌǇŝŵƉĂĐƚĂŶĂůǇƐĞƐ ?KZ “ƵĚŐĞƚĂƌǇ
ŝŵƉĂĐƚĂŶĂůǇƐŝƐ ?KZ “ŶĂůǇƐĞƐďƵĚŐĞƚŝŵƉĂĐƚ ?KZ “ŶĂůǇƐŝƐďƵĚŐĞƚŝŵƉĂĐƚ ?
OR "Análisis del impacto presupuestario" OR "Análise impacto 
orçamentário") OR (N03.219.463.060)) 
AND All fields 
((mh: "Pharmaceutical Preparations" OR "Preparaciones Farmacéuticas" OR 
"Preparações Farmacêuticas") OR (tw: "drugs" OR "medicines" OR 
"medicamentos") OR (VS2.002.001)) 
 
 
Appendix 1C - Search strategy: Central (Cochrane) 
ID Search Hits 
#1 MeSH descriptor: [Pharmaceutical Preparations] explode all trees  
#2 Pharmaceutical Preparations        
#3 Drugs           
#4 Medicines          
#5 #1 or #2 or #3 or #4         
#6 MeSH descriptor: [Budgets] explode all trees     
#7 Budget           
#8 Budget impact          
#9 Budget impact analyses        
#10 Budget impact analysis        
#11 Budget impact models         
#12 Budgetary impact analyses        
#13 Budgetary impact analysis        
#14 Analyses budget impact        
#15 Analysis budget impact         
#16 #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15    
#17 #5 and #16          
 
